| Patient Data . | Number . | Percent . |
|---|---|---|
| Demographics | ||
| Patients | 185 | 100.0% |
| Male | 108 | 58.4% |
| Female | 77 | 41.6% |
| Mean age at diagnosis (range) | 59.5 (23.3–84.6) | |
| Median age at diagnosis | 62.2 | |
| Karnofsky Performance Status | ||
| <70 | 24 | 13.0% |
| ≥70 | 161 | 87.0% |
| Tumor features | ||
| Primary glioblastoma | 185 | 100.0% |
| IDH mutation (IDH1 or IDH2) | 18 | 9.7% |
| MGMT promoter methylationa | 75 | 42.4% |
| Extent of resection | ||
| Gross total resection | 50 | 27.0% |
| Near-total resection | 19 | 10.3% |
| Subtotal resection | 65 | 35.1% |
| Biopsy | 51 | 27.6% |
| Adjuvant treatment | ||
| No adjuvant treatment | 9 | 4.9% |
| Adjuvant treatment | 176 | 95.1% |
| Full chemoradiation | 139 | 75.1% |
| Partial chemoradiation | 37 | 20.0% |
| Patient Data . | Number . | Percent . |
|---|---|---|
| Demographics | ||
| Patients | 185 | 100.0% |
| Male | 108 | 58.4% |
| Female | 77 | 41.6% |
| Mean age at diagnosis (range) | 59.5 (23.3–84.6) | |
| Median age at diagnosis | 62.2 | |
| Karnofsky Performance Status | ||
| <70 | 24 | 13.0% |
| ≥70 | 161 | 87.0% |
| Tumor features | ||
| Primary glioblastoma | 185 | 100.0% |
| IDH mutation (IDH1 or IDH2) | 18 | 9.7% |
| MGMT promoter methylationa | 75 | 42.4% |
| Extent of resection | ||
| Gross total resection | 50 | 27.0% |
| Near-total resection | 19 | 10.3% |
| Subtotal resection | 65 | 35.1% |
| Biopsy | 51 | 27.6% |
| Adjuvant treatment | ||
| No adjuvant treatment | 9 | 4.9% |
| Adjuvant treatment | 176 | 95.1% |
| Full chemoradiation | 139 | 75.1% |
| Partial chemoradiation | 37 | 20.0% |
aCensored, 177 with results.
| Patient Data . | Number . | Percent . |
|---|---|---|
| Demographics | ||
| Patients | 185 | 100.0% |
| Male | 108 | 58.4% |
| Female | 77 | 41.6% |
| Mean age at diagnosis (range) | 59.5 (23.3–84.6) | |
| Median age at diagnosis | 62.2 | |
| Karnofsky Performance Status | ||
| <70 | 24 | 13.0% |
| ≥70 | 161 | 87.0% |
| Tumor features | ||
| Primary glioblastoma | 185 | 100.0% |
| IDH mutation (IDH1 or IDH2) | 18 | 9.7% |
| MGMT promoter methylationa | 75 | 42.4% |
| Extent of resection | ||
| Gross total resection | 50 | 27.0% |
| Near-total resection | 19 | 10.3% |
| Subtotal resection | 65 | 35.1% |
| Biopsy | 51 | 27.6% |
| Adjuvant treatment | ||
| No adjuvant treatment | 9 | 4.9% |
| Adjuvant treatment | 176 | 95.1% |
| Full chemoradiation | 139 | 75.1% |
| Partial chemoradiation | 37 | 20.0% |
| Patient Data . | Number . | Percent . |
|---|---|---|
| Demographics | ||
| Patients | 185 | 100.0% |
| Male | 108 | 58.4% |
| Female | 77 | 41.6% |
| Mean age at diagnosis (range) | 59.5 (23.3–84.6) | |
| Median age at diagnosis | 62.2 | |
| Karnofsky Performance Status | ||
| <70 | 24 | 13.0% |
| ≥70 | 161 | 87.0% |
| Tumor features | ||
| Primary glioblastoma | 185 | 100.0% |
| IDH mutation (IDH1 or IDH2) | 18 | 9.7% |
| MGMT promoter methylationa | 75 | 42.4% |
| Extent of resection | ||
| Gross total resection | 50 | 27.0% |
| Near-total resection | 19 | 10.3% |
| Subtotal resection | 65 | 35.1% |
| Biopsy | 51 | 27.6% |
| Adjuvant treatment | ||
| No adjuvant treatment | 9 | 4.9% |
| Adjuvant treatment | 176 | 95.1% |
| Full chemoradiation | 139 | 75.1% |
| Partial chemoradiation | 37 | 20.0% |
aCensored, 177 with results.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
